Neuronetics Inc
NASDAQ:STIM
Intrinsic Value
Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. [ Read More ]
The intrinsic value of one STIM stock under the Base Case scenario is 4.87 USD. Compared to the current market price of 3.83 USD, Neuronetics Inc is Undervalued by 21%.
Valuation Backtest
Neuronetics Inc
Run backtest to discover the historical profit from buying and selling STIM stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Neuronetics Inc
Current Assets | 93.8m |
Cash & Short-Term Investments | 59.7m |
Receivables | 18.7m |
Other Current Assets | 15.4m |
Non-Current Assets | 22m |
PP&E | 4.8m |
Other Non-Current Assets | 17.3m |
Current Liabilities | 19.8m |
Accounts Payable | 4.8m |
Accrued Liabilities | 12.4m |
Other Current Liabilities | 2.7m |
Non-Current Liabilities | 61.8m |
Long-Term Debt | 59.3m |
Other Non-Current Liabilities | 2.5m |
Earnings Waterfall
Neuronetics Inc
Revenue
|
71.3m
USD
|
Cost of Revenue
|
-19.6m
USD
|
Gross Profit
|
51.7m
USD
|
Operating Expenses
|
-82.3m
USD
|
Operating Income
|
-30.6m
USD
|
Other Expenses
|
365k
USD
|
Net Income
|
-30.2m
USD
|
Free Cash Flow Analysis
Neuronetics Inc
What is Free Cash Flow?
STIM Profitability Score
Profitability Due Diligence
Neuronetics Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Neuronetics Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
STIM Solvency Score
Solvency Due Diligence
Neuronetics Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Neuronetics Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
STIM Price Targets Summary
Neuronetics Inc
According to Wall Street analysts, the average 1-year price target for STIM is 7.14 USD with a low forecast of 6.06 USD and a high forecast of 8.4 USD.
Ownership
STIM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
STIM Price
Neuronetics Inc
Average Annual Return | 13.58% |
Standard Deviation of Annual Returns | 97.49% |
Max Drawdown | -95% |
Market Capitalization | 111.4m USD |
Shares Outstanding | 29 756 100 |
Percentage of Shares Shorted | 0.37% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 175 full-time employees. The company went IPO on 2018-06-28. The firm is focused on designing, developing, and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The firm intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The firm sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
Contact
IPO
Employees
Officers
The intrinsic value of one STIM stock under the Base Case scenario is 4.87 USD.
Compared to the current market price of 3.83 USD, Neuronetics Inc is Undervalued by 21%.